Trial Profile
The efficacy and tolerability of agomelatine in patients with depressive disorders
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2014
Price :
$35
*
At a glance
- Drugs Agomelatine (Primary)
- Indications Depressive disorders
- Focus Adverse reactions; Therapeutic Use
- 14 Jan 2014 New trial record
- 06 Nov 2013 Results presented at the 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.